Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Health-care companies slid after signs of stress in UnitedHealth Group's business. The largest U.S. insurer by enrollees cut its growth projections, citing hitches with its key Medicare business.

Lilly's weight-loss drug trial shows promising results, propelling stock up 14.36%. Goldman Sachs predicts potential $23.5B in sales by 2035.

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

Eli Lilly says its GLP-1 drug in pill form is as safe and effective as Ozempic and other mega-popular injectable drugs for weight loss and lowering blood sugar. The company announ ...

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

Eli Lilly's experimental pill worked as well as blockbuster drug Ozempic to lower weight and blood sugar in a trial of ...